<DOC>
	<DOCNO>NCT01294761</DOCNO>
	<brief_summary>The main objective clinical trial randomize HIV infected patient good HIV control tenofovir ( TDF ) , emtricitabine ( lamivudine ) plus lopinavir/ritonavir ( LPV/r ) switch regimen raltegravir ( RAL ) darunavir/ritonavir ( DRV/r ) continue ongoing regimen compare two group ' estimate glomerular filtration rate ( eGFR ) investigate whether anti-HIV treatment contain TDF reverse-transcriptase inhibitor ( NTRI spar regimen ) protective patient ' renal function virological efficacy comparison standard treatment TDF , .</brief_summary>
	<brief_title>Comparing Continuing Tenofovir , Emtricitabine ( Lamivudine ) Plus Lopinavir Switching Raltegravir Plus Darunavir</brief_title>
	<detailed_description>Eligibility criterion HIV infect outpatient inpatient : without history virological failure include protease inhibitor raltegravir ( disregard whether patient history drug resistance drug holiday , ) take LPV/r+TVD ( TDF+lamivudine ) longer 15 week enrollment HIV viral load le 50 copies/ml 15 week , include blip ( one time episode detectable level HIV viraemia proceed follow undetectable viraemia ) . 20 year old old Japanese willing participate trial able agree inform consent . Main outcome measure investigate estimate glomerular filtration rate ( eGFR ) intervene group RAL+DRV/r improve 10 % intention treat ( ITT ) analysis time 48 week start trial . Other outcome measure : virological efficacy group DRV/r+RAL ( 48 week 96 week ) comparison renal function marker two arm : serum creatinine , urine beta-2 microglobulin , tubular resorption rate phosphate , urine albumin , N-acetyl-beta-glucosaminidase , serum cystatin C , urine protein urine glucose ( 48 week 96 week ) comparison lipid marker two arm : triglyceride , HDL cholesterol , LDL cholesterol total cholesterol ( 48 week 96 week ) discontinuation rate arm , reason time discontinuation treatment change 96 week adverse event arm , symptoms rate 96 week blood plasma concentration level RAL DRV consent intervened case National Center Global Health Medicine</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV infect outpatient inpatient without history virological failure include protease inhibitor raltegravir ( disregard whether patient history drug resistance drug holiday , ) take LPV/r+TVD ( TDF+lamivudine ) longer 15 week enrollment HIV viral load le 50 copies/ml 15 week , include blip ( one time episode detectable level HIV viraemia proceed follow undetectable viraemia ) 20 year old old Japanese willing participate trial able agree inform consent case applicable follow excluded trial HBs antigen positive within 15 week enrollment ( case confirm HBs antibody positive enrol without HBs antigen test ) malabsorption gastrointestinal symptom affect absorption drug , dysphagia case clinical data within 15 week start trial closest date enrollment GPT 2.5 time high normal range ( grade 2 ) eGFR le 60ml/min ( CockcroftGault formula ) case opportunistic infection require treatment ( primary secondary preventive prophylaxis administrate study ) case pregnancy nursing period , possibility pregnancy use drug prohibit combine drug interaction drug trial case decide patient 's physician suitable trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>AIDS</keyword>
	<keyword>Clinical Trials , Randomized</keyword>
</DOC>